Researchers and clinical experts at Hackensack Meridian Health, Edison, NJ, continue their work on convalescent plasma treatments for COVID-19 patients – now with a new Phase 2 study, according to press release.
The researchers at John Theurer Cancer Center at Hackensack University Medical Center, and their colleagues at the Hackensack Meridian Center for Discovery and Innovation (CDI) now will test clinical treatments in an outpatient setting.
The convalescent plasma program at Hackensack University Medical Center identifies the “super donors” with the greatest levels of highly-neutralizing antibodies, independently validated, as determined through methodology developed by CDI experts.
In the Phase 2 study, the plasma from super donors is infused into patients with early-stage COVID-19 infection who have at least one major risk factor for serious disease. The goal is to treat the patients in the first 96 hours in an outpatient setting – with the aim to prevent hospitalization entirely.
